Q1. What are the contributions in this paper?
This item is the archived peer‐reviewed author‐version of: Nanomedicine‐based intraperitoneal therapy for the treatment of peritoneal carcinomatosis – Mission possible ?
Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible?
George R. Dakwar,Molood Shariati,Wouter Willaert,Wim Ceelen,Stefaan C. De Smedt,Katrien Remaut +5 more
TLDR
The current clinical management of PC is discussed, as well as recent advances in nanomedicine‐based IP delivery, which address important challenges to be overcome towards designing optimal nanocarriers for IP therapy in vivo.About:
This article is published in Advanced Drug Delivery Reviews.The article was published on 2017-01-01 and is currently open access. It has received 66 citations till now.read more
Citations
More filters
Journal ArticleDOI
Strategies for Hyaluronic Acid-Based Hydrogel Design in Drug Delivery
TL;DR: The aim of the present review is to highlight and discuss recent advances made in the last years on the design of chemical and physical HA-based hydrogels and their application for biomedical purposes, in particular, drug delivery.
Journal ArticleDOI
Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy.
Ying Xie,Yu Hang,Yazhe Wang,Richard Sleightholm,Dipakkumar R. Prajapati,Johannes Bader,Johannes Bader,Ao Yu,Weimin Tang,Lee Jaramillo,Lee Jaramillo,Jing Li,Rakesh K. Singh,David Oupický +13 more
TL;DR: Data is presented that a local IP delivery of a miRNA/siRNA combination holds the potential to improve pancreatic cancer therapy and shows improved therapeutic effect when compared with individual therapies.
Journal ArticleDOI
Magnetically assisted intraperitoneal drug delivery for cancer chemotherapy.
Milad Shamsi,Amir Sedaghatkish,Morteza Dejam,Mohsen Saghafian,Mehdi Mohammadi,Amir Sanati-Nezhad +5 more
TL;DR: This work proposes a new magnetically assisted strategy to elevate drug penetration into peritoneal tumor nodules and improve IP chemotherapy and shows an order of magnitude increase in the final intratumoral concentration of drug-coated MNPs with respect to free cytotoxic agents.
Journal ArticleDOI
Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2).
Vladimir Khomyakov,Andrey Ryabov,Andrey A. Ivanov,Larisa Bolotina,Anna Utkina,N. N. Volchenko,Andrey Kaprin +6 more
TL;DR: Bidirectional chemotherapy combining XELOX with PIPAC with cisplatin and doxororubicin is well tolerated, can induce objective tumor regression and is associated with a promising survival in PMGC.
Journal ArticleDOI
Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles
Hedi Hunt,Lorena Simón-Gracia,Allan Tobi,Venkata Ramana Kotamraju,Shweta Sharma,Mait Nigul,Kazuki N. Sugahara,Erkki Ruoslahti,Tambet Teesalu,Tambet Teesalu,Tambet Teesalu +10 more
TL;DR: Targeting of p32 with linTT1 tumor‐penetrating peptide improves tumor selectivity and antitumor efficacy of IP pro‐apoptotic NWs, and may represent a general strategy to increase their therapeutic index.
References
More filters
Journal ArticleDOI
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
Donald R. Senger,Stephen J. Galli,Ann M. Dvorak,Carole A. Perruzzi,V. Susan Harvey,Harold F. Dvorak +5 more
TL;DR: Tumor ascites fluids from guinea pigs, hamsters, and mice contain activity that rapidly increases microvascular permeability, and this activity is secreted by these tumor cells and a variety of other tumor cell lines in vitro.
Journal ArticleDOI
Cancer drug resistance: an evolving paradigm
TL;DR: There are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Journal ArticleDOI
Liposomal drug delivery systems: from concept to clinical applications.
TL;DR: Lipidic nanoparticles are the first nanomedicine delivery system to make the transition from concept to clinical application, and they are now an established technology platform with considerable clinical acceptance.
Journal ArticleDOI
PLGA-based nanoparticles: An overview of biomedical applications
Fabienne Danhier,Eduardo Ansorena,Joana M. Silva,Joana M. Silva,Régis Coco,Aude Le Breton,Véronique Préat +6 more
TL;DR: This review presents why PLGA has been chosen to design nanoparticles as drug delivery systems in various biomedical applications such as vaccination, cancer, inflammation and other diseases.
Journal ArticleDOI
Therapeutic Nanoparticles for Drug Delivery in Cancer
TL;DR: In this paper, the authors proposed a passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles, enabling them to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors.